The Effects of Marijuana Exposure on Expiratory Airflow. A Study of Adults who Participated in the U.S. National Health and Nutrition Examination Study
- 1 February 2015
- journal article
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 12 (2) , 135-141
Abstract
Given the inconclusive science on the long-term effects of marijuana exposure on lung function, the increasing tetrahydrocannabinol composition of marijuana over time, and the increasing legal accessibility of the substance, continued investigation is needed. To determine the independent association between recent and chronic marijuana smoke exposure with spirometric parameters of lung function and symptoms of respiratory health in a large cohort of U.S. adults. This is a cross-sectional study of U.S. adults who participated in the National Health and Nutrition Examination Survey cycles from 2007-2008 and 2009-2010, using the data from standardized spirometry and survey questions performed during these years. In the combined 2007-2010 cohort, 59.1% replied that they had used marijuana at least once, and 12.2% had used in the past month. For each additional day of marijuana use in the prior month, there were no changes in percent predicted FEV1 (0.002 ± 0.04%; P = 0.9), but there was an associated increase in percent predicted FVC (0.13 ± 0.03%, P = 0.0001) and decrease in the FEV1/FVC ratio (-0.1 ± 0.04%; P < 0.0001). In multivariable regressions, 1-5 and 6-20 joint-years of marijuana use were not associated with an FEV1/FVC less than 70% (odds ratio [OR] = 1.1, 95% confidence interval [CI] = 0.7-1.6, P = 0.8, and OR = 1.2, 95% CI = 0.8-1.8, P = 0.4, respectively), whereas over 20 joint-years was associated with an FEV1/FVC less than 70% (OR = 2.1; 95% CI = 1.1-3.9; P = 0.02). For each additional marijuana joint-year smoked, there was no associated change in the mean percent predicted FEV1 (0.02 ± 0.02%; P = 1.00), an increase in percent predicted FVC (0.07 ± 0.02%; P = 0.004), and a decrease in FEV1/FVC (-0.03 ± 0.01%; P = 0.02). In a large cross-section of U.S. adults, cumulative lifetime marijuana use, up to 20 joint-years, is not associated with adverse changes in spirometric measures of lung health. Although greater than 20 joint-years of cumulative marijuana exposure was associated with a twofold increased odds of a FEV1/FVC less than 70%, this was the result of an increase in FVC, rather than a disproportional decrease in FEV1 as is typically associated with obstructive lung diseases.Keywords
This publication has 30 references indexed in Scilit:
- Medicinal Use of Marijuana — Polling ResultsNew England Journal of Medicine, 2013
- Potency Trends of Δ9‐THC and Other Cannabinoids in Confiscated Cannabis Preparations from 1993 to 2008*Journal of Forensic Sciences, 2010
- Effects of cannabis on lung function: a population-based cohort studyEuropean Respiratory Journal, 2009
- How to interpret reduced forced expiratory volume in 1 s (FEV1)/vital capacity ratio with normal FEV1European Respiratory Journal, 2009
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Effects of Marijuana Smoking on Pulmonary Function and Respiratory ComplicationsArchives of internal medicine (1960), 2007
- Interpretative strategies for lung function testsEuropean Respiratory Journal, 2005
- Respiratory effects of marijuana and tobacco use in a U.S. sampleJournal of General Internal Medicine, 2005
- Impairment of Antimicrobial Activity and Nitric Oxide Production in Alveolar Macrophages from Smokers of Marijuana and CocaineThe Journal of Infectious Diseases, 2003
- Pulmonary Hazards of Smoking Marijuana as Compared with TobaccoNew England Journal of Medicine, 1988